168 related articles for article (PubMed ID: 10845912)
21. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.
Sixma JJ; Schiphorst ME; Verweij CL; Pannekoek H
Eur J Biochem; 1991 Mar; 196(2):369-75. PubMed ID: 1901037
[TBL] [Abstract][Full Text] [Related]
22. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
[TBL] [Abstract][Full Text] [Related]
23. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
[TBL] [Abstract][Full Text] [Related]
24. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
Matsushita T; Sadler JE
J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
[TBL] [Abstract][Full Text] [Related]
25. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
Obert B; Houllier A; Meyer D; Girma JP
Blood; 1999 Mar; 93(6):1959-68. PubMed ID: 10068669
[TBL] [Abstract][Full Text] [Related]
26. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
Ribba AS; Voorberg J; Meyer D; Pannekoek H; Pietu G
J Biol Chem; 1992 Nov; 267(32):23209-15. PubMed ID: 1429668
[TBL] [Abstract][Full Text] [Related]
27. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
[TBL] [Abstract][Full Text] [Related]
28. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
[TBL] [Abstract][Full Text] [Related]
29. Defect of heparin binding in plasma and recombinant von Willebrand factor with type 2 von Willebrand disease mutations.
Rastegar-Lari G; Ajzenberg N; Ribba AS; Vereycken-Holler V; Legendre P; Villoutreix B; Meyer D; Baruch D
Thromb Haemost; 2001 Dec; 86(6):1459-65. PubMed ID: 11776314
[TBL] [Abstract][Full Text] [Related]
30. Identification of a new type 2M von Willebrand disease mutation also at position 1324 of von Willebrand factor.
Hilbert L; Fressinaud E; Ribba AS; Meyer D; Mazurier C;
Thromb Haemost; 2002 Apr; 87(4):635-40. PubMed ID: 12008946
[TBL] [Abstract][Full Text] [Related]
31. von Willebrand disease type 1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergistically determine a 2M phenotype in four Italian patients.
Pagliari MT; Baronciani L; Stufano F; Garcia-Oya I; Cozzi G; Franchi F; Peyvandi F
Haemophilia; 2016 Nov; 22(6):e502-e511. PubMed ID: 27785872
[TBL] [Abstract][Full Text] [Related]
32. GPIbα-vWF rolling under shear stress shows differences between type 2B and 2M von Willebrand disease.
Coburn LA; Damaraju VS; Dozic S; Eskin SG; Cruz MA; McIntire LV
Biophys J; 2011 Jan; 100(2):304-12. PubMed ID: 21244826
[TBL] [Abstract][Full Text] [Related]
33. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
[TBL] [Abstract][Full Text] [Related]
34. Expressed full-length von Willebrand factor containing missense mutations linked to type IIB von Willebrand disease shows enhanced binding to platelets.
Kroner PA; Kluessendorf ML; Scott JP; Montgomery RR
Blood; 1992 Apr; 79(8):2048-55. PubMed ID: 1373334
[TBL] [Abstract][Full Text] [Related]
35. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
[TBL] [Abstract][Full Text] [Related]
36. Platelet aggregation by membrane-expressed A1 domains of von Willebrand Factor is dependent on residues Asp 560 and Gly 561.
Schulte am Esch J; Robson SC; Cruz MA
Biochem Biophys Res Commun; 2003 Mar; 302(4):873-7. PubMed ID: 12646253
[TBL] [Abstract][Full Text] [Related]
37. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
[TBL] [Abstract][Full Text] [Related]
38. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
39. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding.
Baronciani L; Federici AB; Beretta M; Cozzi G; Canciani MT; Mannucci PM
J Thromb Haemost; 2005 Dec; 3(12):2689-94. PubMed ID: 16246252
[TBL] [Abstract][Full Text] [Related]
40. von Willebrand factor without the A2 domain is resistant to proteolysis.
Lankhof H; Damas C; Schiphorst ME; Ijsseldijk MJ; Bracke M; Furlan M; Tsai HM; de Groot PG; Sixma JJ; Vink T
Thromb Haemost; 1997 May; 77(5):1008-13. PubMed ID: 9184419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
